CD274 and cancer: Another interesting study based on liposomal co-delivery of imatinib (IMT) and siRNA-PD-L1 showed promising results towards enhancement of the cancer immunity cycle by knockdown of programmed cell death ligand 1 (PD-L1) which in turn prevented the PDL1-mediated immunosuppression of tumor-specific CTLs (Li and Han, 2020).